Roivant Sciences (ROIV) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ROIV Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.10 |
| 52 Week High | US$22.45 |
| 52 Week Low | US$8.73 |
| Beta | 1.23 |
| 1 Month Change | 8.92% |
| 3 Month Change | 55.85% |
| 1 Year Change | 82.64% |
| 3 Year Change | 235.36% |
| 5 Year Change | 121.00% |
| Change since IPO | 112.50% |
Recent News & Updates
Recent updates
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced
Nov 13Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Apr 23Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21%
Feb 12
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Feb 05
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Roivant Sciences: A Biotech Growth Play With Major Ambitions
Dec 04Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18Shareholder Returns
| ROIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.3% | -0.9% | -0.6% |
| 1Y | 82.6% | 20.5% | 12.4% |
Return vs Industry: ROIV exceeded the US Biotechs industry which returned 20.5% over the past year.
Return vs Market: ROIV exceeded the US Market which returned 12.4% over the past year.
Price Volatility
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ROIV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 750 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
Roivant Sciences Ltd. Fundamentals Summary
| ROIV fundamental statistics | |
|---|---|
| Market cap | US$15.37b |
| Earnings (TTM) | -US$700.99m |
| Revenue (TTM) | US$20.33m |
Is ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIV income statement (TTM) | |
|---|---|
| Revenue | US$20.33m |
| Cost of Revenue | US$602.05m |
| Gross Profit | -US$581.72m |
| Other Expenses | US$119.27m |
| Earnings | -US$700.99m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | -2,861.53% |
| Net Profit Margin | -3,448.22% |
| Debt/Equity Ratio | 0% |
How did ROIV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 20:16 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roivant Sciences Ltd. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |